Silvia de Muga

Hospital Del Mar — Spain

Medicine · Health Sciences

13h-index638citations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(9), Bladder and Urothelial Cancer Treatments(8), PI3K/AKT/mTOR signaling in cancer(5), Lung Cancer Treatments and Mutations(4), Fibroblast Growth Factor Research(4)

Publications22 total

Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG
Molecular Biology Reports·2026
Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC
OncoImmunology·2019· 35 citedOpen Access
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression
Oncotarget·2017· 23 citedOpen Access
FOXO1 down-regulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression
Human Pathology·2017· 20 cited
Concurrent<i>TMPRSS2-ERG</i>and<i>SLC45A3-ERG</i>rearrangements plus<i>PTEN</i>loss are not found in low grade prostate cancer and define an aggressive tumor subset
The Prostate·2016· 18 cited
Association of <i>ERG</i> and <i>TMPRSS2‐ERG</i> with grade, stage, and prognosis of prostate cancer is dependent on their expression levels
The Prostate·2015· 65 cited
<scp>HER2</scp> as a target in invasive urothelial carcinoma
Cancer Medicine·2015· 56 citedOpen Access
Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology·2014· 28 cited
Ros1 Rearrangements and Copy Number Alterations in Nsclc Patients: High Frequency of Ros1 Deletions
Annals of Oncology·2014· 1 cited
Identification of ALK Gene Alterations in Urothelial Carcinoma
PLoS ONE·2014· 12 citedOpen Access
CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement
Cancer Biomarkers·2013· 13 cited
A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer
American Journal Of Pathology·2012· 67 citedOpen Access
Multidimensional investigation of HER2 in advanced urothelial carcinoma (UC).
Journal of Clinical Oncology·2012
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
Human Pathology·2012· 62 cited
7159 POSTER Mutations in FGFR3 and Ras in Urothelial Cell Carcinomas of the Bladder – No Association With MAPK Pathway Activation
European Journal of Cancer·2011
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
Modern Pathology·2010· 51 citedOpen Access
803 PI3K signalling pathway is activated by PIK3CA gain and overexpression in prostate tumours, but PI3KCA, BRAF, KRAS AND AKT1 mutations are an infrequent event
European Journal of Cancer Supplements·2010
816 FGFR3 mutations in prostate cancer and other tumours
European Journal of Cancer Supplements·2010
Abstract 1168: Urothelial cell carcinomas harbor very frequent mutations in FGFR3-PI3K-AKT pathway and highest prevalence of mutations is related to low-grade tumors
Cancer Research·2010
Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas
Modern Pathology·2010· 69 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Josep Lloreta(15), Marta Lorenzo(14), Laia Agell(12), Sílvia Hernández(11), Sérgio Serrano(10), Núria Juanpere(10), José A. Lorente(9), Marta Salido(9), Alba Font‐Tello(4), Raquel Esgueva(3), Lluís Fumadó(3), Laia Serrano(3), Joaquim Bellmunt(3), Lillian Werner(3), David M. Berman(3), Jonathan E. Rosenberg(3), Sílvia Menéndez(3), Lluís Cecchini(3), N. Juanpere(3), Núria Juanpere(2)